1
|
Hounsome L, Eyre TA, Ireland R, Hodson A, Walewska R, Ardeshna K, Chaganti S, McKay P, Davies A, Fox CP, Kalakonda N, Fields PA. Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England. Br J Cancer 2022; 126:134-143. [PMID: 34611308 PMCID: PMC8727618 DOI: 10.1038/s41416-021-01525-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Revised: 07/10/2021] [Accepted: 08/11/2021] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND We wished to examine treatment and outcome patterns in older diffuse large B-cell lymphoma (DLBCL) patients, with a focus on the effect of route-to-diagnosis to outcome. METHODS Data were extracted from Public Health England's National Cancer Registration and Analysis Service between 2013 and 2015 included route-to-diagnosis, disease characteristics and survival for 9186 patients ≥65 years. Systemic Anti-Cancer Therapy data identified front-line regimens, cycles and doses. RESULTS Route-to-diagnosis were emergency (34%), NHS urgent cancer pathway (rapid haemato-oncologist review <2 weeks), (29%) and standard GP referral (25%). The most common regimen was R-CHOP (n = 4392). 313 patients received R-miniCHOP (7% of R-CHOP). For all patients, 3-year overall survival (OS) for 65-79 years was 57% and for ≥80 years was 32%. Three-year OS for R-CHOP-treated patients diagnosed via emergency presentation was 54% (adjusted hazard ratio (HR) 1.63, p < 0.01) and 75% (adjusted HR 0.81, p < 0.01) on the NHS urgent cancer pathway (reference HR:1.00: GP referrals). 3-year OS was 54% for both R-miniCHOP and R-CHOP in ≥80 years. CONCLUSIONS Our comprehensive population analysis is the first to show that the NHS urgent cancer pathway is associated with a superior survival after adjusting for multiple confounders. Equivalent survival for R-CHOP and R-mini-CHOP was demonstrated in those ≥80 years.
Collapse
Affiliation(s)
- L. Hounsome
- grid.271308.f0000 0004 5909 016XPublic Health England, London, UK
| | - T. A. Eyre
- grid.410556.30000 0001 0440 1440Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - R. Ireland
- grid.13097.3c0000 0001 2322 6764Department of Haematology, Kings College London Hospitals, London, UK
| | - A. Hodson
- grid.414810.80000 0004 0399 2412Department of Haematology, Ipswich Hospital, Ipswich, UK
| | - R. Walewska
- Department of Haematology, University Hospitals Dorset, Bournemouth, UK
| | - K. Ardeshna
- grid.52996.310000 0000 8937 2257Department of Haematology, UCLH, London, UK
| | - S. Chaganti
- grid.412563.70000 0004 0376 6589Department of Haematology, University Hospitals Birmingham, Birmingham, UK
| | - P. McKay
- Department of Haematology, Beatson Cancer Centre, Glasgow, UK
| | - A. Davies
- grid.123047.30000000103590315Department of Medical Oncology, Southampton General Hospital, Southampton, UK
| | - C. P. Fox
- grid.240404.60000 0001 0440 1889Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - N. Kalakonda
- grid.10025.360000 0004 1936 8470Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - P. A. Fields
- grid.425213.3Department of Haematology, Guys and St Thomas’ Hospital, London, UK
| |
Collapse
|
2
|
Salles G, Duell J, González Barca E, Jurczak W, Liberati A, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Zinzani P, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Maddocks K. PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND). Hematol Oncol 2019. [DOI: 10.1002/hon.130_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. Salles
- Hospices Civils de Lyon; Centre Hospitalier Lyon Sud, Service d'Hématologie; Pierre-Bénite France
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - E. González Barca
- Department of Hematology; Institut Catalá d'Oncología, Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - A. Obr
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - G. Gaidano
- Division of Haematology; Department of Translational Medicine, University of Eastern Piedmont; Novara Italy
| | - M. Andre
- Department of Hematology; Université catholique de Louvain, CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haemato-oncology; Clatterbridge Cancer Centre and University of Liverpool; Wirral United Kingdom
| | - M. Dreyling
- Department of Medicine III; University Hospital of Ludwig-Maximilians-Universität; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Department of Biostatistics and Data Management; MorphoSys AG; Planneg Germany
| | - S. Ambarkhane
- Department of Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine; Division of Hematology, The Ohio State University Comprehensive Cancer Center; Columbus Ohio United States
| |
Collapse
|
3
|
Radford J, Connors J, Younes A, Gallamini A, Ansell S, Kim W, Cheong J, Flinn I, Kalakonda N, Kaminski M, Pettengell R, Onsum M, Josephson N, Kuroda S, Liu R, Miao H, Gautam A, Trepicchio W, Sureda A. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | - J.M. Connors
- Centre for Lymphoid Cancer; British Columbia Cancer Centre for Lymphoid Cancer; Vancouver Canada
| | - A. Younes
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Gallamini
- Research; Innovation and Statistics Department, A Lacassagne Cancer Centre; Nice France
| | - S.M. Ansell
- Department of Medicine; Mayo Clinic; Rochester United States
| | - W.S. Kim
- Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - J. Cheong
- Division of Hematology; Department of Internal Medicine, Yonsei University College of Medicine; Seoul Republic of Korea
| | - I. Flinn
- Department of Oncology; Sarah Cannon Research Institute; Nashville United States
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - M. Kaminski
- Internal Medicine; University of Michigan; Ann Arbor United States
| | - R. Pettengell
- Haematology; St George's Hospital; London United Kingdom
| | - M. Onsum
- Biomarkers; Seattle Genetics, Inc.; Bothell United States
| | - N. Josephson
- Clinical Development; Seattle Genetics, Inc.; Bothell United States
| | - S. Kuroda
- Biostatistics; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited; Osaka Japan
| | - R. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - H. Miao
- OTAU Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - W.L. Trepicchio
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Sureda
- Clinical Hematology; Institut Català d'Oncologia - Hospital Duran i Reynals; Barcelona Spain
| |
Collapse
|
4
|
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, Oluyadi A, McCarthy D, Ma X, Corona K, Shah J, Van Den Neste E, Canales M. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.31_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - F. Cavallo
- Molecular Biotechnology and Health Sciences; Aziena Ospedaliero - Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - G. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge United Kingdom
| | - A. Goy
- Oncology; Hackensack University Medical Center; Hackensack United States
| | - J. Vermaat
- Hematology; Leiden University Medical Center; Leiden Netherlands
| | | | - O. Lavee
- Hematology; St. Vincent's Hospital Sydney; Darlinghurst Australia
| | - M. Maerevoet
- Hematology; Service Hématologie, Institut Bordet; Bruxelles Belgium
| | - J. Zijlstra
- Hematology; Amsterdam UMC; Amsterdam Netherlands
| | - S. Bakshi
- Medical Oncology; Dr. B. R. A. Institute Rotary Cancer Hospital; New Delhi India
| | - R. Bouabdallah
- Oncology/Hematology; Institut Paoli-Calmettes; Marseille France
| | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - R. Gurion
- Hematology; Rabin MC; Petah Tiqwa Israel
| | - B. Hill
- Hematology and Medical Oncology; Cleveland Clinic Main Campus; Cleveland United States
| | - U. Jaeger
- Medicine I; Medical University of Vienna; Vienna Austria
| | - J. Sancho
- Clinical Hematology; Hospital Germans Trias i Pujol; Barcelona Spain
| | - M. Schuster
- Medicine; Stony Brook University; Stony Brook United States
| | | | - F. De la Cruz
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Egyed
- Hematology; Teaching Hospital Mór Kaposi; Kaposvár Hungary
| | - S. Mishra
- Medical Oncology; Institute of Medical Sciences & SUM Hospital; Bhubaneswar India
| | | | | | - K. Warzocha
- Hematology; Instytut Hematologii i Transfuzjologii; Warszawa Poland
| | - A. Oluyadi
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - D. McCarthy
- Clinical Operations; Karyopharm Therapeutics Inc.; Newton United States
| | - X. Ma
- Biostatistics; Karyopharm Therapeutics Inc.; Newton United States
| | - K. Corona
- Medical Affairs; Karyopharm Therapeutics Inc.; Newton United States
| | - J. Shah
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - E. Van Den Neste
- Hematology; Cliniques Universitaires Saint-Luc; Brussels Belgium
| | - M. Canales
- Medicine; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|
5
|
Pettitt A, Barrington S, Kalakonda N, Khan U, Jackson R, Carruthers S, Oates M, Lin K, Ardeshna K, Eyre T, Fox C, Kennedy B, Linton K, Malladi R, Menne T, Okosun J, Paneesha S, Rule S, Johnston A, Trotman J. NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.35_2629] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A.R. Pettitt
- Department of Molecular and Clinical Cancer Medicine; University of Liverpool, Liverpool Health Partners; Liverpool United Kingdom
| | - S. Barrington
- School of Biomedical Engineering and Imaging Sciences; St Thomas’ Hospital, Kings College London; London United Kingdom
| | - N. Kalakonda
- Department of Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - U.T. Khan
- Department of Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - R. Jackson
- CR-UK Liverpool Cancer Trials Unit; University of Liverpool; Liverpool United Kingdom
| | - S. Carruthers
- CR-UK Liverpool Cancer Trials Unit; University of Liverpool; Liverpool United Kingdom
| | - M. Oates
- Department of Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - K. Lin
- Haemato-Oncology Diagnostic Service; Liverpool Clinical Laboratories; Liverpool United Kingdom
| | - K. Ardeshna
- Department of Haematology; University College London; London United Kingdom
| | - T. Eyre
- Department of Haematology; Churchill Hospital; Oxford United Kingdom
| | - C.P. Fox
- Department of Clinical Haematology; Nottingham University Hospitals NHS Trust; Nottingham United Kingdom
| | - B. Kennedy
- Department of Haematology; University Hospital Leicester NHS Trust; Leicester United Kingdom
| | - K. Linton
- Department of Haemato-oncology; Manchester Cancer Research Centre; Manchester United Kingdom
| | - R. Malladi
- Department of Haematology; Queen Elizabeth Medical Centre; Birmingham United Kingdom
| | - T. Menne
- Department of Haematology; Royal Freeman Hospital; Newcastle Upon Tyne United Kingdom
| | - J. Okosun
- Centre for Haemato-Oncology; Barts Cancer Institute, Queen Mary University of London; London United Kingdom
| | - S. Paneesha
- Department of Haematology; Heartlands Hospital; Birmingham United Kingdom
| | - S. Rule
- Department of Haematology; Derriford Hospital; Plymouth United Kingdom
| | - A. Johnston
- School of Medicine & Department of Haematology; University of Tasmania & Royal Hobart Hospital; Hobart Australia
| | - J. Trotman
- University of Sydney; Concord Repatriation General Hospital; Concord New South Wales Australia
| |
Collapse
|
6
|
Linley A, Kalakonda N, MacEwan D, Prior I, Slupsky J. PF370 SIGNAL-OMICS ANALYSIS OF THE IMPACT OF THERAPY ON BCR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKAEMIA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000559692.06651.82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
7
|
Pettitt A, Kalakonda N, Cicconi S, Murphy C, Menon G, Coupland S, Oates M, Lin K, Pocock C, Jenkins S, Schuh A, Wandroo F, Rassam S, Duncombe A, Cervi P, Paneesha S, Aldouri M, Fox C, Knechtli C, Hamblin M, Turner D, Hillmen P. BRIEF CO-ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG-TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3-YEAR FOLLOW-UP FROM THE RIALTO TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.32_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Pettitt
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - S. Cicconi
- CR-UK Liverpool Cancer Trials Unit; University of Liverpool; Liverpool United Kingdom
| | - C. Murphy
- CR-UK Liverpool Cancer Trials Unit; University of Liverpool; Liverpool United Kingdom
| | - G. Menon
- Liverpool Clinical Laboratories; Haemato-Oncology Diagnostic Service; Liverpool United Kingdom
| | - S.E. Coupland
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - M. Oates
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - K. Lin
- Liverpool Clinical Laboratories; Department of Blood Sciences; Liverpool United Kingdom
| | - C. Pocock
- Department of Haematology; Kent & Canterbury Hospital; Canterbury United Kingdom
| | - S. Jenkins
- Russells Hall Hospital; Haematology Unit; Dudley United Kingdom
| | - A. Schuh
- Department of Oncology; University of Oxford; Oxford United Kingdom
| | - F. Wandroo
- Department of Haematology; Sandwell Hospital; Birmingham United Kingdom
| | - S. Rassam
- Department of Haematology; Maidstone Hospital; Maidstone United Kingdom
| | - A.S. Duncombe
- Department of Haematology; University Hospital Southampton; Southampton United Kingdom
| | - P. Cervi
- Department of Haematology & Blood Transfusion; Southend Hospital; Southend United Kingdom
| | - S. Paneesha
- Department of Haematology; Heartlands Hospital; Birmingham United Kingdom
| | - M. Aldouri
- Department of Haematology; Medway Maritime Hospital; Gillingham United Kingdom
| | - C. Fox
- Department of Clinical Haematology; Nottingham University Hospitals NHS Trust; Nottingham United Kingdom
| | - C. Knechtli
- Department of Clinical Haematology; Royal United Hospital; Bath United Kingdom
| | - M. Hamblin
- Department of Haematology; Colchester General Hospital; Colchester United Kingdom
| | - D. Turner
- Oncology Unit; Torbay Hospital; Torquay United Kingdom
| | - P. Hillmen
- Faculty of Medicine and Health; University of Leeds; Leeds United Kingdom
| |
Collapse
|
8
|
Till K, Gallardo Zapata J, Marks T, Weaver D, Pachter J, Abdullah M, Kalakonda N, Pettitt A, Slupsky J. POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES. Hematol Oncol 2019. [DOI: 10.1002/hon.194_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- K.J. Till
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - J. Gallardo Zapata
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - T. Marks
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - J.A. Pachter
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - M. Abdullah
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - A.R. Pettitt
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - J.R. Slupsky
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| |
Collapse
|
9
|
Nowakowski G, Willenbacher W, Greil R, Larsen T, Patel K, Jäger U, Manges R, Trümper L, Haioun C, Everaus H, Kalakonda N, Knoble J, de Nully Brown P, Jørgensen J, Cunningham D, Domper Rubio N, Casadebaig M, Manzke O, Munoz J. SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R 2
-CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL. Hematol Oncol 2019. [DOI: 10.1002/hon.93_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - W. Willenbacher
- Department of Hematology and Oncology; Innsbruck Medical University; Innsbruck Austria
| | - R. Greil
- Department of Hematology; Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Cancer Cluster; Salzburg Austria
| | - T.S. Larsen
- Department of Hematology; Odense University Hospital; Odense Denmark
| | - K. Patel
- Center for Blood Disorders and Stem Cell Transplant; Swedish Cancer Institute; Seattle United States
| | - U. Jäger
- Department of Hematology; Medical University of Vienna; Vienna Austria
| | - R.F. Manges
- Hematology/Oncology; Parkview Health; Fort Wayne United States
| | - L. Trümper
- Abteilung für Hämatologie und Onkologie; Universitätsmedizin Göttingen; Göttingen Germany
| | - C. Haioun
- Lymphoid Malignancies Unit; Henri Mondor University Hospital, University Hospital, APHP; Créteil France
| | - H. Everaus
- Department of Hematology-Oncology; Tartu University Hospital; Tartu Estonia
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - J. Knoble
- Medical Oncology and Hematology; Mark H. Zangmeister Cancer Center; Columbus United States
| | - P. de Nully Brown
- Department of Hematology; Rigshospitalet, Copenhagen University Hospital; København Denmark
| | - J.M. Jørgensen
- Departments of Clinical Medicine and Hematology; Aarhus University Hospital; Aarhus Denmark
| | - D. Cunningham
- Gastrointestinal and Lymphoma Unit; The Royal Marsden Hospital; London United Kingdom
| | - N. Domper Rubio
- Global Clinical R&D; Celgene International; Boudry Switzerland
| | - M. Casadebaig
- Statistics; Celgene International; Boudry Switzerland
| | - O. Manzke
- Global Clinical R&D; Celgene International; Boudry Switzerland
| | - J. Munoz
- Medical Oncology; Banner MD Anderson Cancer Center; Gilbert United States
| |
Collapse
|
10
|
Salles G, González Barca E, Jurczak W, Liberati A, Duell J, Nagy Z, Papajík T, Andre M, Kalakonda N, Dreyling M, Zinzani P, Ambarkhane S, Weirather J, Maddocks K. L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_35] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- G. Salles
- Service d'Hématologie, Hospices Civils de Lyon; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - E. González Barca
- Department of Hematology, Institut Catalá d'Oncología; Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - T. Papajík
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - M. Andre
- Department of Hematology, Université catholique de Louvain; CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haematology; Royal Liverpool University Hospital; Liverpool UK
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; University Hospital of LMU; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine, Division of Hematology; The Ohio State University Comprehensive Cancer Center; Columbus Ohio USA
| |
Collapse
|
11
|
Pettitt A, Kalakonda N, Polydoros F, Bickerstaff M, Menon G, Coupland S, Oates M, Lin K, Pocock C, Jenkins S, Schuh A, Wandroo F, Rassam S, Duncombe A, Jenner M, Cervi P, Paneesha S, Aldouri M, Fox C, Knechtli C, Hamblin M, Turner D, Hillmen P. EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A.R. Pettitt
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool UK
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool UK
| | - F. Polydoros
- CRUK Liverpool Cancer Trials Unit; University of Liverpool; Liverpool UK
| | - M. Bickerstaff
- CRUK Liverpool Cancer Trials Unit; University of Liverpool; Liverpool UK
| | - G. Menon
- Haemato-Oncology Diagnostic Service; Liverpool Clinical Laboratories; Liverpool UK
| | - S.E. Coupland
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool UK
| | - M. Oates
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool UK
| | - K. Lin
- Blood Sciences; Liverpool Clinical Laboratories; Liverpool UK
| | - C. Pocock
- Department of Haematology; Kent & Canterbury Hospital; Canterbury UK
| | - S. Jenkins
- Haematology Unit; Russells Hall Hospital; Dudley UK
| | - A. Schuh
- Oncology; University of Oxford; Oxford UK
| | - F. Wandroo
- Haematology; Sandwell Hospital; Birmingham UK
| | - S. Rassam
- Haematology; Maidstone Hospital; Maidstone UK
| | - A.S. Duncombe
- Haematology; University Hospital Southampton; Southampton UK
| | - M. Jenner
- Haematology; University Hospital Southampton; Southampton UK
| | - P. Cervi
- Haematology & Blood Transfusion; Southend Hospital, Westcliff-on-Sea; UK
| | - S. Paneesha
- Haematology; Heartlands Hospital; Birmingham UK
| | - M. Aldouri
- Haematology; Medway Maritime Hospital; Gillingham UK
| | - C.P. Fox
- Clinical Haematology; Nottingham University Hospitals NHS Trust; Nottingham UK
| | - C. Knechtli
- Clinical Haematology; Royal United Hospital; Bath UK
| | - M. Hamblin
- Haematology; Colchester General Hospital; Colchester UK
| | - D. Turner
- Oncology Unit; Torbay Hospital; Torquay UK
| | - P. Hillmen
- Medicine and Health; University of Leeds; Leeds UK
| |
Collapse
|
12
|
Gleeson M, Peckitt C, To Y, Edwards L, Chau I, Johnson P, Ardeshna K, Wotherspoon A, Attygalle A, Begum R, Chua S, Zerizer I, Hawkes E, Macheta M, Collins G, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D. CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_63] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Gleeson
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - C. Peckitt
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - Y.M. To
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - L. Edwards
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - I. Chau
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - P. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| | - K.M. Ardeshna
- Department of Haematology; University College Hospital; London UK
| | - A. Wotherspoon
- Department of Histopathology; The Royal Marsden Hospital; London UK
| | - A. Attygalle
- Department of Histopathology; The Royal Marsden Hospital; London UK
| | - R. Begum
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - S. Chua
- Department of Radiology; The Royal Marsden Hospital; Sutton UK
| | - I. Zerizer
- Department of Radiology; The Royal Marsden Hospital; Sutton UK
| | - E.A. Hawkes
- Department of Oncology Research; Eastern Health; Melbourne Australia
| | - M.P. Macheta
- Department of Haematology; Blackpool Victoria Hospital; Blackpool UK
| | - G.P. Collins
- Oxford Cancer and Haematology Centre; Churchill Hospital; Oxford UK
| | - J.A. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | - A. Forbes
- Department of Haematology; Royal Cornwall Hospital; Truro UK
| | - A. Hart
- Department of Haematology; New Victoria Hospital; Glasgow UK
| | - S. Montoto
- Department of Haemato-oncology; St Bartholomew's Hospital; London UK
| | - P. McKay
- Department of Haematology; The Beatson West of Scotland Cancer Centre; Glasgow UK
| | - K. Benstead
- Department of Oncology; Gloucestershire Hospitals NHS Foundation Trust; Gloucester UK
| | - N. Morley
- Department of Haematology; Royal Hallamshire Hospital; Sheffield UK
| | - N. Kalakonda
- Department of Haematology; Royal Liverpool University Hospital; Liverpool UK
| | - Y. Hasan
- Department of Haematology; Sandwell and West Birmingham Hospitals NHS Trust; West Bromwich UK
| | - D. Turner
- Department of Haematology; Torbay Hospital; Torquay UK
| | - D. Cunningham
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| |
Collapse
|
13
|
Gleeson M, Peckitt C, Cunningham D, To Y, Edwards L, Chau I, Johnson P, Ardeshna K, Wotherspoon A, Attygalle A, Begum R, Zerizer I, Hawkes E, Macheta M, Collins G, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Chua S. THE ROLE OF 18F FDG-PET/CT IN PERIPHERAL T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI MULTICENTRE PHASE II RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Gleeson
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - C. Peckitt
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - D. Cunningham
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - Y.M. To
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - L. Edwards
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - I. Chau
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - P. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| | - K.M. Ardeshna
- Department of Haematology; University College Hospital; London UK
| | - A. Wotherspoon
- Department of Histopathology; The Royal Marsden Hospital; London UK
| | - A. Attygalle
- Department of Histopathology; The Royal Marsden Hospital; London UK
| | - R. Begum
- GI and Lymphoma Unit; The Royal Marsden Hospital; Sutton UK
| | - I. Zerizer
- Department of Radiology; The Royal Marsden Hospital; Sutton UK
| | - E.A. Hawkes
- Department of Oncology; Eastern Health; Melbourne Australia
| | - M.P. Macheta
- Department of Haematology; Blackpool Teaching Hospitals; Blackpool UK
| | - G.P. Collins
- Oxford Cancer and Haematology Centre; Churchill Hospital; Oxford UK
| | - J.A. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | - A. Forbes
- Department of Haematology; Royal Cornwall Hospital; Truro UK
| | - A. Hart
- Department of Haematology; New Victoria Hospital; Glasgow UK
| | - S. Montoto
- Department of Haemato-oncology; St Bartholomew's Hospital; London UK
| | - P. McKay
- Department of Haematology; Beatson West of Scotland Cancer Centre; Glasgow UK
| | - K. Benstead
- Department of Oncology, Gloucestershire Hospitals NHS Foundation Trust; Gloucester UK
| | - N. Morley
- Department of Haematology; Royal Hallamshire Hospital; Sheffield UK
| | - N. Kalakonda
- Department of Haematology; Royal Liverpool University Hospital; Liverpool UK
| | - Y. Hasan
- Department of Haematology, Sandwell and West Birmingham Hospitals NHS Trust; West Bromwich UK
| | - D. Turner
- Department of Haematology; Torbay Hospital; Torquay UK
| | - S. Chua
- Department of Radiology; The Royal Marsden Hospital; Sutton UK
| |
Collapse
|
14
|
Jaeger U, Kalakonda N, Everaus H, Fustier P, Jaeger J, Manzke O, Nowakowski G. PHASE II STUDY OF DURVALUMAB (ANTI-PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- U. Jaeger
- Division of Hematology and Hemostaseology; Medical University of Vienna; Vienna Austria
| | - N. Kalakonda
- Department of Molecular and Clinical Cancer Medicine; Royal Liverpool University Hospital; Liverpool UK
| | - H. Everaus
- Department of Hematology and Oncology; Tartu Ulikooli Kliinikum; Tartu Estonia
| | - P. Fustier
- Hematology/Oncology; Celgene Corporation; Boudry Switzerland
| | - J. Jaeger
- BioStats; Celgene Corporation; Boudry Switzerland
| | - O. Manzke
- Hematology/Oncology; Celgene Corporation; Boudry Switzerland
| | | |
Collapse
|
15
|
Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Drake L, Klimek V, Dhodapkar M, Teruya-Feldstein J, Hedvat C, Kalakonda N, Fleisher M, Filippa D, Qin J, Nimer SD, Comenzo RL. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone Marrow Transplant 2005; 35:441-7. [PMID: 15640822 DOI: 10.1038/sj.bmt.1704779] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Multiple myeloma (MM) is an incurable hematologic malignancy for which autologous hematopoietic stem cell transplantation (HCT) is a standard therapy. The optimal method of stem cell mobilization is not defined. We evaluated intravenous melphalan (60 mg/m2), the most effective agent for MM, and G-CSF (10 microg/kg/day) for mobilization. End points were safety, adequacy of CD34+ collections, MM response, and contamination of stem cell components (SCC). In total, 32 patients were mobilized. There were no deaths or significant bleeding episodes; 14 patients (44%) required hospitalization for neutropenic fever. Median days of grade 3 or 4 neutropenia or thrombocytopenia were 7 (2-20) and 8 (3-17). Median mobilization days, CD34+ cells/kg and total leukaphereses were 16 (12-30), 12.1 million (2.6-52.8), and 2 (1-5) respectively. Four patients (12.5 %) failed to achieve the target of 4 million CD34+ cells/kg in five leukaphereses. Reduction in myeloma was seen in 11 patients (34%) with 3 (9%) achieving complete response; 15 (47%) maintained prior responses. Estimated MM contamination per SCC (N=48) was 0.0009% (range 0-0.1) and 0.21 x 10(4) cells per kg (range 0-41.2). Increased contamination was associated with increased patient age. This strategy for mobilization is feasible, frequently requires hospitalization and transfusion, and controls disease in most patients.
Collapse
Affiliation(s)
- S Gupta
- Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, Chitale DA, Moscowitz C, Dhodapkar MV, Teruya-Feldstein J, Filippa D, Comenzo RL. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol 2004; 124:309-14. [PMID: 14717777 DOI: 10.1046/j.1365-2141.2003.04779.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Systemic AL amyloidosis (AL) is a disorder in which light chains form fibrillar deposits, leading to organ dysfunction and death. Rarely, AL has been associated with non-Hodgkin's lymphoma (NHL), although this association has not been well characterized. We report a series of six patients with AL associated with NHL, primarily lymphoplasmacytic lymphoma. Organ involvement was variable, with frequent bulky lymphadenopathy and visceral cavity deposits, but no cardiac involvement. Positron emission tomography scans were negative. Bone marrow and lymph node biopsies showed a mixed population of CD20+ lymphoid and CD138+ plasma cells. Serum free light chains were elevated, and correlated with response to therapy. Immunoglobulin light chain variable region (Ig VL) germline gene use was typical for AL, reflecting previously observed correlations between germline gene use and organ tropism. Five patients received rituximab-based therapies with two responses. Two patients underwent autologous stem cell transplantation with one complete haematological response. Four patients survive at 10-132 months from diagnosis. AL with NHL has distinctive clinical features but employs the same Ig VL gene repertoire as AL with clonal plasma cell dyscrasias. Serial serum free light chain levels are useful for tracking response to therapy. Treatments aimed at both lymphoid and plasma cell components appear warranted.
Collapse
Affiliation(s)
- A D Cohen
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001; 98:1555-60. [PMID: 11520807 DOI: 10.1182/blood.v98.5.1555] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Activating point mutations in codons 12, 13, or 61 of the K-ras and N-ras genes have been reported to occur in up to 40% of patients with multiple myeloma at presentation. In a study of 34 presentation myeloma cases using a sensitive polymerase chain reaction-restriction fragment length polymorphism strategy on enriched tumor cell populations, the present study detected N-ras codon 61 mutation-positive cells in all patients. Quantitative plaque hybridization using allele-specific oligonucleotide probes showed that in the majority of patients, ras mutation-positive cells comprise only a subpopulation of the total malignant plasma cell compartment (range, 12%-100%). Using clonospecific point mutations in the 5' untranslated region of the BCL6 gene to quantitate clonal B cells in FACS-sorted bone marrow populations from 2 patients, the representation of ras mutation-positive cells was independent of immunophenotype. These observations imply that mutational activation of N-ras codon 61 is a mandatory event in the pathogenesis of multiple myeloma; such mutations provide a marker of intraclonal heterogeneity that may originate at an earlier ontologic stage than immunophenotypic diversification of the malignant B cell clone.
Collapse
Affiliation(s)
- N Kalakonda
- CRC Gene Regulation Group, Paterson Institute for Cancer Research, and CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
| | | | | | | |
Collapse
|